Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder

Linda J. Bristow; Jyoti Gulia; Michael R. Weed; Bettadapura N. Srikumar; Yu Wen Li; John D. Graef; Pattipati S. Naidu; Charulatha Sanmathi; Jayant Aher; Tanmaya Bastia; Mahesh Paschapur; Narasimharaju Kalidindi; Kuchibhotla Vijaya Kumar; Thaddeus Molski; Rick Pieschl; Alda Fernandes; Jeffrey M. Brown; Digavalli V. Sivarao; Kimberly Newberry; Mark Bookbinder; Joseph Polino; Deborah Keavy; Amy Newton; Eric Shields; Jean Simmermacher; James Kempson; Jianqing Li; Huiping Zhang; Arvind Mathur; Raja Reddy Kallem; Meenakshee Sinha; Manjunath Ramarao; Reeba K. Vikramadithyan; Srinivasan Thangathirupathy; Jayakumar Warrier; Imadul Islam; Joanne J. Bronson; Richard E. Olson; John E. Macor; Charlie F. Albright; Dalton King; Lorin A. Thompson; Lawrence R. Marcin; Michael Sinz

doi:10.1124/jpet.117.242784

Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder

Linda J. Bristow
, Jyoti Gulia
, Michael R. Weed
, Bettadapura N. Srikumar
, Yu Wen Li
, John D. Graef
, Pattipati S. Naidu
, Charulatha Sanmathi
, Jayant Aher
, Tanmaya Bastia
, Mahesh Paschapur
, Narasimharaju Kalidindi
, Kuchibhotla Vijaya Kumar
, Thaddeus Molski
, Rick Pieschl
, Alda Fernandes
, Jeffrey M. Brown
, Digavalli V. Sivarao
, Kimberly Newberry
, Mark Bookbinder

Joseph Polino, Deborah Keavy, Amy Newton, Eric Shields, Jean Simmermacher, James Kempson, Jianqing Li, Huiping Zhang, Arvind Mathur, Raja Reddy Kallem, Meenakshee Sinha, Manjunath Ramarao, Reeba K. Vikramadithyan, Srinivasan Thangathirupathy, Jayakumar Warrier, Imadul Islam, Joanne J. Bronson, Richard E. Olson, John E. Macor, Charlie F. Albright, Dalton King, Lorin A. Thompson, Lawrence R. Marcin, Michael Sinz

Department of Pharmaceutical Sciences

Bristol-Myers Squibb

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	377-393
Number of pages	17
Journal	Journal of Pharmacology and Experimental Therapeutics
Volume	363
Issue number	3
DOIs	https://doi.org/10.1124/jpet.117.242784
State	Published - Dec 2017

ASJC Scopus Subject Areas

Molecular Medicine
Pharmacology

Access to Document

10.1124/jpet.117.242784

Cite this

Bristow, L. J., Gulia, J., Weed, M. R., Srikumar, B. N., Li, Y. W., Graef, J. D., Naidu, P. S., Sanmathi, C., Aher, J., Bastia, T., Paschapur, M., Kalidindi, N., Kumar, K. V., Molski, T., Pieschl, R., Fernandes, A., Brown, J. M., Sivarao, D. V., Newberry, K., ... Sinz, M. (2017). Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder. Journal of Pharmacology and Experimental Therapeutics, 363(3), 377-393. https://doi.org/10.1124/jpet.117.242784

Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder. / Bristow, Linda J.; Gulia, Jyoti; Weed, Michael R. et al.
In: Journal of Pharmacology and Experimental Therapeutics, Vol. 363, No. 3, 12.2017, p. 377-393.

Research output: Contribution to journal › Article › peer-review

Bristow, LJ, Gulia, J, Weed, MR, Srikumar, BN, Li, YW, Graef, JD, Naidu, PS, Sanmathi, C, Aher, J, Bastia, T, Paschapur, M, Kalidindi, N, Kumar, KV, Molski, T, Pieschl, R, Fernandes, A, Brown, JM, Sivarao, DV, Newberry, K, Bookbinder, M, Polino, J, Keavy, D, Newton, A, Shields, E, Simmermacher, J, Kempson, J, Li, J, Zhang, H, Mathur, A, Kallem, RR, Sinha, M, Ramarao, M, Vikramadithyan, RK, Thangathirupathy, S, Warrier, J, Islam, I, Bronson, JJ, Olson, RE, Macor, JE, Albright, CF, King, D, Thompson, LA, Marcin, LR & Sinz, M 2017, 'Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder', Journal of Pharmacology and Experimental Therapeutics, vol. 363, no. 3, pp. 377-393. https://doi.org/10.1124/jpet.117.242784

Bristow LJ, Gulia J, Weed MR, Srikumar BN, Li YW, Graef JD et al. Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder. Journal of Pharmacology and Experimental Therapeutics. 2017 Dec;363(3):377-393. doi: 10.1124/jpet.117.242784

Bristow, Linda J. ; Gulia, Jyoti ; Weed, Michael R. et al. / Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder. In: Journal of Pharmacology and Experimental Therapeutics. 2017 ; Vol. 363, No. 3. pp. 377-393.

@article{86dad389e3684f948797e0e1ae5100e3,

title = "Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder",

author = "Bristow, \{Linda J.\} and Jyoti Gulia and Weed, \{Michael R.\} and Srikumar, \{Bettadapura N.\} and Li, \{Yu Wen\} and Graef, \{John D.\} and Naidu, \{Pattipati S.\} and Charulatha Sanmathi and Jayant Aher and Tanmaya Bastia and Mahesh Paschapur and Narasimharaju Kalidindi and Kumar, \{Kuchibhotla Vijaya\} and Thaddeus Molski and Rick Pieschl and Alda Fernandes and Brown, \{Jeffrey M.\} and Sivarao, \{Digavalli V.\} and Kimberly Newberry and Mark Bookbinder and Joseph Polino and Deborah Keavy and Amy Newton and Eric Shields and Jean Simmermacher and James Kempson and Jianqing Li and Huiping Zhang and Arvind Mathur and Kallem, \{Raja Reddy\} and Meenakshee Sinha and Manjunath Ramarao and Vikramadithyan, \{Reeba K.\} and Srinivasan Thangathirupathy and Jayakumar Warrier and Imadul Islam and Bronson, \{Joanne J.\} and Olson, \{Richard E.\} and Macor, \{John E.\} and Albright, \{Charlie F.\} and Dalton King and Thompson, \{Lorin A.\} and Marcin, \{Lawrence R.\} and Michael Sinz",

note = "Publisher Copyright: Copyright {\textcopyright} 2017 by The American Society for Pharmacology and Experimental Therapeutics",

year = "2017",

month = dec,

doi = "10.1124/jpet.117.242784",

language = "English",

volume = "363",

pages = "377--393",

journal = "Journal of Pharmacology and Experimental Therapeutics",

issn = "0022-3565",

number = "3",

}

TY - JOUR

T1 - Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder

AU - Bristow, Linda J.

AU - Gulia, Jyoti

AU - Weed, Michael R.

AU - Srikumar, Bettadapura N.

AU - Li, Yu Wen

AU - Graef, John D.

AU - Naidu, Pattipati S.

AU - Sanmathi, Charulatha

AU - Aher, Jayant

AU - Bastia, Tanmaya

AU - Paschapur, Mahesh

AU - Kalidindi, Narasimharaju

AU - Kumar, Kuchibhotla Vijaya

AU - Molski, Thaddeus

AU - Pieschl, Rick

AU - Fernandes, Alda

AU - Brown, Jeffrey M.

AU - Sivarao, Digavalli V.

AU - Newberry, Kimberly

AU - Bookbinder, Mark

AU - Polino, Joseph

AU - Keavy, Deborah

AU - Newton, Amy

AU - Shields, Eric

AU - Simmermacher, Jean

AU - Kempson, James

AU - Li, Jianqing

AU - Zhang, Huiping

AU - Mathur, Arvind

AU - Kallem, Raja Reddy

AU - Sinha, Meenakshee

AU - Ramarao, Manjunath

AU - Vikramadithyan, Reeba K.

AU - Thangathirupathy, Srinivasan

AU - Warrier, Jayakumar

AU - Islam, Imadul

AU - Bronson, Joanne J.

AU - Olson, Richard E.

AU - Macor, John E.

AU - Albright, Charlie F.

AU - King, Dalton

AU - Thompson, Lorin A.

AU - Marcin, Lawrence R.

AU - Sinz, Michael

PY - 2017/12

Y1 - 2017/12

UR - https://www.scopus.com/pages/publications/85034731596

UR - https://www.scopus.com/pages/publications/85034731596#tab=citedBy

U2 - 10.1124/jpet.117.242784

DO - 10.1124/jpet.117.242784

M3 - Article

C2 - 28954811

AN - SCOPUS:85034731596

SN - 0022-3565

VL - 363

SP - 377

EP - 393

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

IS - 3

ER -

Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this